Search research articles
Contact Us
Filters
Showing results (411-420 of 504) with videos related to
Page
of 51
Sort By:
Haematologica
|
July 11, 2019
HIF-1α is over-expressed in leukemic cells from <i>TP53</i>-disrupted patients and is a promising therapeutic target in chronic lymphocytic leukemia
Valentina Griggio, Candida Vitale, Maria Todaro, et al.
Haematologica
|
April 11, 2020
Comparative analysis of targeted next-generation sequencing panels for the detection of gene mutations in chronic lymphocytic leukemia: an ERIC multi-center study
Lesley-Ann Sutton, Viktor Ljungström, Anna Enjuanes, et al.
Leukemia
|
June 24, 2024
Early reappearance of intraclonal proliferative subpopulations in ibrutinib-resistant chronic lymphocytic leukemia
Federico Pozzo, Gabriela Forestieri, Filippo Vit, et al.
Blood
|
June 24, 2016
The genetics of nodal marginal zone lymphoma
Valeria Spina, Hossein Khiabanian, Monica Messina, et al.
British Journal of Haematology
|
May 23, 2018
Biallelic BIRC3 inactivation in chronic lymphocytic leukaemia patients with 11q deletion identifies a subgroup with very aggressive disease
Sara Raponi, Ilaria Del Giudice, Caterina Ilari, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
April 28, 2021
Short Diagnosis-to-Treatment Interval Is Associated With Higher Circulating Tumor DNA Levels in Diffuse Large B-Cell Lymphoma
Stefan Alig, Charles W Macaulay, David M Kurtz, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
January 14, 2010
Expression of mutated IGHV3-23 genes in chronic lymphocytic leukemia identifies a disease subset with peculiar clinical and biological features
Riccardo Bomben, Michele Dal-Bo, Dania Benedetti, et al.
Hemasphere
|
March 18, 2025
Loss of CYLD promotes splenic marginal zone lymphoma
Athanasios Pseftogas, Jessica Bordini, Silvia Heltai, et al.
Journal of Geriatric Oncology
|
June 17, 2026
Patient-reported outcomes in BRUIN CLL-321: A randomized phase 3 trial comparing pirtobrutinib to investigators choice of idelalisib plus rituximab or bendamustine plus rituximab in patients with relapsed/refractory chronic lymphocytic leukemia/small lymphocytic lymphoma in the post-cBTKi setting
Paolo Ghia, Davide Rossi, Emmanuelle Ferrant, et al.
Haematologica
|
April 29, 2022
Resistance to PI3Kδ inhibitors in marginal zone lymphoma can be reverted by targeting the IL-6/PDGFRA axis
Alberto J Arribas, Sara Napoli, Luciano Cascione, et al.
Page
of 51
Search research articles
Search
Showing results (411-420 of 504) with videos related to
Sort By:
Page
of 51
Haematologica
|
July 11, 2019
HIF-1α is over-expressed in leukemic cells from <i>TP53</i>-disrupted patients and is a promising therapeutic target in chronic lymphocytic leukemia
Valentina Griggio, Candida Vitale, Maria Todaro, et al.
Haematologica
|
April 11, 2020
Comparative analysis of targeted next-generation sequencing panels for the detection of gene mutations in chronic lymphocytic leukemia: an ERIC multi-center study
Lesley-Ann Sutton, Viktor Ljungström, Anna Enjuanes, et al.
Leukemia
|
June 24, 2024
Early reappearance of intraclonal proliferative subpopulations in ibrutinib-resistant chronic lymphocytic leukemia
Federico Pozzo, Gabriela Forestieri, Filippo Vit, et al.
Blood
|
June 24, 2016
The genetics of nodal marginal zone lymphoma
Valeria Spina, Hossein Khiabanian, Monica Messina, et al.
British Journal of Haematology
|
May 23, 2018
Biallelic BIRC3 inactivation in chronic lymphocytic leukaemia patients with 11q deletion identifies a subgroup with very aggressive disease
Sara Raponi, Ilaria Del Giudice, Caterina Ilari, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
April 28, 2021
Short Diagnosis-to-Treatment Interval Is Associated With Higher Circulating Tumor DNA Levels in Diffuse Large B-Cell Lymphoma
Stefan Alig, Charles W Macaulay, David M Kurtz, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
January 14, 2010
Expression of mutated IGHV3-23 genes in chronic lymphocytic leukemia identifies a disease subset with peculiar clinical and biological features
Riccardo Bomben, Michele Dal-Bo, Dania Benedetti, et al.
Hemasphere
|
March 18, 2025
Loss of CYLD promotes splenic marginal zone lymphoma
Athanasios Pseftogas, Jessica Bordini, Silvia Heltai, et al.
Journal of Geriatric Oncology
|
June 17, 2026
Patient-reported outcomes in BRUIN CLL-321: A randomized phase 3 trial comparing pirtobrutinib to investigators choice of idelalisib plus rituximab or bendamustine plus rituximab in patients with relapsed/refractory chronic lymphocytic leukemia/small lymphocytic lymphoma in the post-cBTKi setting
Paolo Ghia, Davide Rossi, Emmanuelle Ferrant, et al.
Haematologica
|
April 29, 2022
Resistance to PI3Kδ inhibitors in marginal zone lymphoma can be reverted by targeting the IL-6/PDGFRA axis
Alberto J Arribas, Sara Napoli, Luciano Cascione, et al.
Page
of 51